Silexion Therapeutics Corp

SLXN Nasdaq SEC CIK 2022416
Follow Silexion Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
EPS, diluted $13.70 −98% vs same quarter last year
Operating cash flow −$2.1M +25.7% vs same quarter last year
Operating income −$2.7M +18.5% vs same quarter last year
Net income by quarter
−$1.7M
−$4.4M
Q4 24 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$10.8M
FY24−$8.4M
FY23−$4.5M
FY22-